Kyle Hagge’s Post

Ending the day with insightful reflections! 💪✨ Today, I tuned in for the second episode of Pharma Insights by Platforce. 🎙️Dr. Yvette Schollmeier, Martijn van den Corput, Stefan Repin, and Juliana Maria Kreisel delved into the operational distinctions between startups and large companies in the Pharma, Beauty, Life Sciences, and Biosciences sectors. Watching experts discuss brand strategies, marketing dynamics, and CRM intricacies is always valuable. 🚀 Thanks for generously sharing your knowledge and experiences. The topics explored today will definitely spark some interesting and meaningful conversations within the Platforce team.  For those unable to attend, stay tuned for the webinar recording on the Platforce page! 😉   #PlatforceWebinar #PharmaInsights #Healthcare #Pharma 

From the point of view of intangible assets, Key Alliance Capital is one of the pillars of the value of Intellectual Capital 🙌🔝🍀 It is very important to work to strengthen it every day🙌

What are the 𝐤𝐞𝐲 𝐩𝐡𝐚𝐫𝐦𝐚 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐡𝐞𝐚𝐥𝐭𝐡 𝐧𝐞𝐰𝐬 & 𝐩𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬 of the first semester of 2024? A few weeks ago, I stumbled upon this amazing work by Gary Monk on LinkedIn, showcasing the main digital pharma collaborations in a single image. Brilliant! 👏 But let's be honest, this is just the tip of the iceberg. 🌐 What other groundbreaking partnerships are out there? 💡 Want to be part of the next collaboration map? 🤝 Let's inspire more collaborations together! 🚀 #digitalpharma #pharmaindustry #collaboration #innovation #healthcare

In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:

In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:

In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:

In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:

In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:

The Agenda for the #FierceNPP Summit 2024 is Now Available! Don't miss out on our best deal yet – save up to $600 off Early Bird Rates for a limited time only by registering now 🔗https://ow.ly/Zz2v50SJjye This Year's Agenda Topics: 👉 Maximize Market Impact: Optimize your pipeline and prioritize decisions to propel your business forward. 👉 Forecasting Mastery: Analyze market and competitive intelligence to create accurate forecasts. 👉 Synergize for Success: Drive collaboration between R&D, clinical, and commercial teams to launch products with precision. 👉 Brand Messaging Brilliance: Develop a compelling brand message to adapt to market demands. 👉 Unparalleled Networking co-located Fierce Biotech Summit: Enjoy the unique opportunity to network with industry leaders during combined meals, breaks, and receptions, and gain exclusive access to the prestigious Fierce Biotech Fierce 15 awards ceremony. FULL AGENDA HERE: https://ow.ly/Zx5v50SJjyc #WeAreFierce #FiercePharma #FierceBiotech#FierceNPP #NewProductPlanning #Boston #Commercialization #ProductPlanning #ProductCommercialization #LifeSciences #MarketLaunch #CommercialExcellence #GoToMarketStrategy #ProductLifecycleManagement

In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media: